Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Affiliation country
Publication year range
1.
Org Biomol Chem ; 12(40): 8048-60, 2014 Oct 28.
Article in English | MEDLINE | ID: mdl-25184371

ABSTRACT

A series of piperidine-based derivatives were identified as novel and potent inhibitors of the influenza virus through structural modification of a compound that was selected from a high-throughput screen. Various analogues were synthesized and confirmed as inhibitors. The structure­activity relationship (SAR) studies suggested that the ether linkage between the quinoline and piperidine is critical for the inhibitory activity. The optimized compound tert-butyl 4-(quinolin-4-yloxy)piperidine-1-carboxylate 11e had an excellent inhibitory activity against influenza virus infection from a variety of influenza virus strains, with EC50 values as low as 0.05 µM. The selectivity index value (SI = MLD50/EC50) of 11e is over 160000 based on cytotoxicity, measured by MTT assays of three cell lines. We carried out a time-of-addition experiment to delineate the mechanism of inhibition. The result indicates that 11e interferes with the early to middle stage of influenza virus replication.


Subject(s)
Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Drug Discovery , Orthomyxoviridae/drug effects , Piperidines/chemistry , Piperidines/pharmacology , Animals , Antiviral Agents/chemical synthesis , Dogs , HEK293 Cells , HeLa Cells , Humans , Madin Darby Canine Kidney Cells , Microbial Sensitivity Tests , Molecular Structure , Structure-Activity Relationship
2.
PLoS One ; 10(3): e0122536, 2015.
Article in English | MEDLINE | ID: mdl-25803288

ABSTRACT

New inhibitors of influenza viruses are needed to combat the potential emergence of novel human influenza viruses. We have identified a class of small molecules that inhibit replication of influenza virus at picomolar concentrations in plaque reduction assays. The compound also inhibits replication of vesicular stomatitis virus. Time of addition and dilution experiments with influenza virus indicated that an early time point of infection was blocked and that inhibitor 136 tightly bound to virions. Using fluorescently labeled influenza virus, inhibition of viral fusion to cellular membranes by blocked lipid mixing was established as the mechanism of action for this class of inhibitors. Stabilization of the neutral pH form of hemagglutinin (HA) was ruled out by trypsin digestion studies in vitro and with conformation specific HA antibodies within cells. Direct visualization of 136 treated influenza virions at pH 7.5 or acidified to pH 5.0 showed that virions remain intact and that glycoproteins become disorganized as expected when HA undergoes a conformational change. This suggests that exposure of the fusion peptide at low pH is not inhibited but lipid mixing is inhibited, a different mechanism than previously reported fusion inhibitors. We hypothesize that this new class of inhibitors intercalate into the virus envelope altering the structure of the viral envelope required for fusion to cellular membranes.


Subject(s)
Influenza A Virus, H3N2 Subtype , Norbornanes/pharmacology , Thiazolidines/pharmacology , Viral Fusion Protein Inhibitors/pharmacology , Virion/drug effects , Virus Internalization/drug effects , Animals , Dogs , Electrophoresis, Polyacrylamide Gel , Fluorescence , HeLa Cells , Humans , Hydrogen-Ion Concentration , Madin Darby Canine Kidney Cells , Microscopy, Electron , Norbornanes/metabolism , Tetrazolium Salts , Thiazoles , Thiazolidines/metabolism , Trypsin , Viral Plaque Assay , Virion/ultrastructure
SELECTION OF CITATIONS
SEARCH DETAIL